Article History
Received: 15 September 2023
Accepted: 2 November 2023
First Online: 19 December 2023
Declarations
:
: YM has served as a speaker of AbbVie; received research funding from Japan Foundation for Applied Enzymology; and is an endowed chair of AbbVie, JIMRO, Zeria Pharmaceutical, Kyorin Pharmaceutical, Mochida Pharmaceutical, Otsuka Holdings, and EA Pharma. D. Choi has served as a speaker bureau for Janssen Pharmaceuticals and as a consultant for Abbvie, Bristol-Myers Squibb, Janssen Pharmaceuticals, Prometheus Laboratory, and Boehringer Ingelheim. XD and JH have no disclosure. DTR has received grant support from Takeda, and has served as a consultant for Abbvie, Altrubio, Allergan Inc., Arena Pharmaceuticals, Aslan Pharmaceuticals, Athos Therapeutics, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Connect BioPharma, GalenPharma/Atlantica, Genentech/Roche, Glycominds, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Materia Prima, Pfizer, Prometheus Biosciences, Reistone, Takeda, and Techlab Inc.
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards, with approval from the Institutional Review Board at the University of Chicago.